Literature DB >> 29141160

Advanced Non-Small-Cell Lung Cancer.

Martin Reck1,2, Klaus F Rabe1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29141160     DOI： 10.1056/NEJMc1712794

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors.

Authors:  Aurélien Brindel; Wajd Althakfi; Marc Barritault; Emmanuel Watkin; Jean-Michel Maury; Pierre-Paul Bringuier; Nicolas Girard; Marie Brevet
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

2.  Astragaloside IV Inhibits the Progression of Non-Small Cell Lung Cancer Through the Akt/GSK-3β/β-Catenin Pathway.

Authors:  Liwei Jia; Dongying Lv; Shuang Zhang; Zhenyue Wang; Bo Zhou
Journal:  Oncol Res       Date:  2018-08-21       Impact factor: 4.938

3.  Circular RNA circRHOT1 contributes to pathogenesis of non-small cell lung cancer by epigenetically enhancing C-MYC expression through recruiting KAT5.

Authors:  Xiaoyan Ren; Jiangang Yu; Lili Guo; Hong Ma
Journal:  Aging (Albany NY)       Date:  2021-08-18       Impact factor: 5.682

4.  Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials.

Authors:  Huan Deng; Li Wang; Xinling Chen; Shujuan Zhang; Fengming Yi; Yiping Wei; Wenxiong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

Review 5.  New Frontiers for Molecular Pathology.

Authors:  Joanna Domagala-Kulawik
Journal:  Front Med (Lausanne)       Date:  2019-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.